<strong>Background:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">Pericoronary fat stranding (PCFS) is a novel noninvasive imag...<strong>Background:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">Pericoronary fat stranding (PCFS) is a novel noninvasive imaging sign of coronary inflammation, and has important implications for cardiovascular risk stratification, and the outcome of percutaneous coronary intervention (PCI) for coronary heart disease patients with pericoronary fat stranding remains unknown. </span><b><span style="font-family:Verdana;">Aim: </span></b><span style="font-family:Verdana;">We report two rare cases of PCI-treated coronary heart disease patients with severe PCFS. </span><b><span style="font-family:Verdana;">Case Presentation: </span></b><span style="font-family:Verdana;">This is the first report of two rare cases of PCI for patients with coronary heart disease surrounded by severe PCFS. We demonstrated that the outcome in these cases is poor, and in-stent restenosis or occlusion occurs rapidly within 2</span></span><span style="font-family:;" "=""></span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">6 months following PCI. However, Case 2 underwent coronary artery bypass grafting after the rapid occurrence of in-stent occlusion, and the bypass graft remained intact over the 5 years following coronary artery bypass grafting. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">Coronary artery bypass grafting rather than PCI may be appropriate for coronary heart disease patients with severe PCFS.</span></span>展开更多
Astragali Radix(AR), a traditional Chinese medicine(TCM), has demonstrated therapeutic efficacy against various diseases, including cardiovascular conditions, over centuries of use.While doxorubicin serves as an effec...Astragali Radix(AR), a traditional Chinese medicine(TCM), has demonstrated therapeutic efficacy against various diseases, including cardiovascular conditions, over centuries of use.While doxorubicin serves as an effective chemotherapeutic agent against multiple cancers, its clinical application remains constrained by significant cardiotoxicity. Research has indicated that AR exhibits protective properties against doxorubicin-induced cardiomyopathy(DIC);however, the specific bioactive components and underlying mechanisms responsible for this therapeutic effect remain incompletely understood. This investigation seeks to identify the protective bioactive components in AR against DIC and elucidate their mechanisms of action.Through network medicine analysis, astragaloside Ⅳ(AsⅣ) and formononetin(FMT) were identified as potential cardioprotective agents from 129 AR components. In vitro experiments using H9c2 rat cardiomyocytes revealed that the AsⅣ-FMT combination(AFC) effectively reduced doxorubicin-induced cell death in a dose-dependent manner, with optimal efficacy at a 1∶2 ratio. In vivo, AFC enhanced survival rates and improved cardiac function in both acute and chronic DIC mouse models. Additionally, AFC demonstrated cardiac protection while maintaining doxorubicin's anti-cancer efficacy in a breast cancer mouse model. Lipidomic and metabolomics analyses revealed that AFC normalized doxorubicin-induced lipid profile alterations, particularly by reducing fatty acid accumulation. Gene knockdown studies and inhibitor experiments in H9c2 cells demonstrated that AsⅣ and FMT upregulated peroxisome proliferator activated receptor γ coactivator 1α(PGC-1α) and PPARα, respectively, two key proteins involved in fatty acid metabolism. This research establishes AFC as a promising therapeutic approach for DIC, highlighting the significance of multi-target therapies derived from natural herbals in contemporary medicine.展开更多
文摘<strong>Background:</strong> <span style="font-family:;" "=""><span style="font-family:Verdana;">Pericoronary fat stranding (PCFS) is a novel noninvasive imaging sign of coronary inflammation, and has important implications for cardiovascular risk stratification, and the outcome of percutaneous coronary intervention (PCI) for coronary heart disease patients with pericoronary fat stranding remains unknown. </span><b><span style="font-family:Verdana;">Aim: </span></b><span style="font-family:Verdana;">We report two rare cases of PCI-treated coronary heart disease patients with severe PCFS. </span><b><span style="font-family:Verdana;">Case Presentation: </span></b><span style="font-family:Verdana;">This is the first report of two rare cases of PCI for patients with coronary heart disease surrounded by severe PCFS. We demonstrated that the outcome in these cases is poor, and in-stent restenosis or occlusion occurs rapidly within 2</span></span><span style="font-family:;" "=""></span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;"> </span><span style="font-family:;" "=""><span style="font-family:Verdana;">6 months following PCI. However, Case 2 underwent coronary artery bypass grafting after the rapid occurrence of in-stent occlusion, and the bypass graft remained intact over the 5 years following coronary artery bypass grafting. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">Coronary artery bypass grafting rather than PCI may be appropriate for coronary heart disease patients with severe PCFS.</span></span>
基金supported by the National Natural Science Foundation of China(No.82173947).
文摘Astragali Radix(AR), a traditional Chinese medicine(TCM), has demonstrated therapeutic efficacy against various diseases, including cardiovascular conditions, over centuries of use.While doxorubicin serves as an effective chemotherapeutic agent against multiple cancers, its clinical application remains constrained by significant cardiotoxicity. Research has indicated that AR exhibits protective properties against doxorubicin-induced cardiomyopathy(DIC);however, the specific bioactive components and underlying mechanisms responsible for this therapeutic effect remain incompletely understood. This investigation seeks to identify the protective bioactive components in AR against DIC and elucidate their mechanisms of action.Through network medicine analysis, astragaloside Ⅳ(AsⅣ) and formononetin(FMT) were identified as potential cardioprotective agents from 129 AR components. In vitro experiments using H9c2 rat cardiomyocytes revealed that the AsⅣ-FMT combination(AFC) effectively reduced doxorubicin-induced cell death in a dose-dependent manner, with optimal efficacy at a 1∶2 ratio. In vivo, AFC enhanced survival rates and improved cardiac function in both acute and chronic DIC mouse models. Additionally, AFC demonstrated cardiac protection while maintaining doxorubicin's anti-cancer efficacy in a breast cancer mouse model. Lipidomic and metabolomics analyses revealed that AFC normalized doxorubicin-induced lipid profile alterations, particularly by reducing fatty acid accumulation. Gene knockdown studies and inhibitor experiments in H9c2 cells demonstrated that AsⅣ and FMT upregulated peroxisome proliferator activated receptor γ coactivator 1α(PGC-1α) and PPARα, respectively, two key proteins involved in fatty acid metabolism. This research establishes AFC as a promising therapeutic approach for DIC, highlighting the significance of multi-target therapies derived from natural herbals in contemporary medicine.
